We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Iconic Labs Plc | LSE:ICON | London | Ordinary Share | GB00BRBJ3P08 | ORD GBP0.0001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Health & Allied Services,nec | 0 | 4.77M | 0.5697 | 0.09 | 418.58k |
TIDMWDC
RNS Number : 3942C
WideCells Group PLC
17 June 2019
17 June 2019
WideCells Group PLC ("WideCells" or the "Company")
Conversion Notice
WideCells Group PLC, announces that, following the issuance of the Prospectus on 22 February 2019, and pursuant to the financing agreement entered into by the Company and the European High Growth Opportunities Securitization Fund (the "Investor") (see RNS dated 6 November 2018), pursuant to which the Company issued bonds ("Convertible Bonds") convertible into ordinary shares of GBP0.0025 each in the Company ("Ordinary Shares") to the Investor, the Company has received a further notice of exercise from the Investor in respect of the exercise by the Investor of its conversion rights under the Convertible Bonds for the aggregate principal amount of GBP400,000, resulting in the issue to the Investor of 100,000,000 new Ordinary Shares ("Conversion Shares").
The Company has agreed, subject only to Admission (as defined below), to issue the Conversion Shares and accordingly application will be made for the Conversion Shares to be listed on the Standard segment of the Official List of the UK Listing Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc ("Admission").
Admission is expected to take place on 23 May 2019. The Conversion Shares will rank pari passu in all respects with all existing Ordinary Shares.
Following Admission of the Conversion Shares, the Company's enlarged issued share capital will compromise 1,090,552,698 Ordinary Shares with voting rights. The Company does not hold any shares in treasury. The figure of 1,090,552,698 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Market Abuse Regulation (MAR) Disclosure - certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
ENDS
For further information, please visit the Company's website https://www.iconiclabs.co.uk/ or contact:
Shard Capital Partners Broker - Damon Heath & Erik Tel: +44 (0) 20 7186 LLP Woolgar 9950 St Brides Partners PR - Melissa Hancock & Isabel Tel: +44 (0) 20 7236 Limited de Salis 1177
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
CONSFWESMFUSESM
(END) Dow Jones Newswires
June 17, 2019 02:24 ET (06:24 GMT)
1 Year Iconic Labs Chart |
1 Month Iconic Labs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions